POM-V Prescription Required Companion Animal

Finilac 50 microgram/ml Oral Solution for Dogs and Cats

Active ingredient: Cabergoline

Form

Liquid

Species

Cats Dogs

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/5023

What it's used for

Suppression of lactation in bitches and queens.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cabergoline

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Finilac 50 microgram/ml Oral Solution for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Suppression of lactation in bitches and queens.

The veterinary medicinal product should be administered orally either directly into the
mouth or by mixing with food.
The dosage is 0.1 ml/kg bodyweight (equivalent to 5 microgram/kg bodyweight of
cabergoline) once daily for 4-6 consecutive days, depending on the severity of the
clinical condition.
If the signs fail to resolve after a single course of treatment, or if they recur after the
end of treatment, then the course of treatment may be repeated.
To ensure a correct dosage, body weight should be determined as accurately as
possible.

Amended pages: June 2025
AN: 03180/2023 & 03179/2023Page 4 of 6

Do not use in pregnant animals since the veterinary medicinal product may cause
abortion.
Do not use with dopamine antagonists.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Cabergoline may induce transient hypotension in treated animals. Do not use in
animals currently being treated with hypotensive drugs. Do not use directly after
surgery whilst the animal is still under the influence of anaesthetic agents.

Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Drowsiness
a
, Anorexia
a
Vomiting
a,b
Neurological symptom (e.g. somnolence, muscle
tremor, ataxia, hyperactivity, convulsion)
Very Rare
(<1 animal / 10,000 treated,
including isolated reports):
Hypotension
c
Allergic reaction (e.g. allergic oedema, urticaria,
allergic dermatitis, pruritus)
a
usually moderate and transient
b
usually only occurs after the first administration. In this case treatment should not
be discontinued, since the vomiting is unlikely to reoccur after the next
administration.
c
transient
Cats:
Very Rare
(<1 animal / 10,000 treated,
including isolated reports):
Drowsiness
a
Allergic reaction (e.g. allergic oedema, urticaria,
allergic dermatitis, pruritus)
Neurological symptom (e.g. somnolence, muscle
tremor, ataxia, hyperactivity, convulsion)
Hypotension
b
Undetermined frequency
(cannot be estimated from the
available data)
Anorexia
a
Vomiting
a,c
a
usually moderate and transient

Amended pages: June 2025
AN: 03180/2023 & 03179/2023Page 3 of 6
b
transient
c
usually only occurs after the first administration. In this case treatment should not
be discontinued, since the vomiting is unlikely to reoccur after the next
administration.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Amended pages: June 2025
AN: 03180/2023 & 03179/2023Page 2 of 6

Special precautions for safe use in the target species:
Caution is recommended in animals with significantly impaired liver function.
Additional supportive treatments should involve restriction of water and carbohydrate
intake and increased exercise.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Wash hands after use.
Avoid contact with skin and eyes. Wash off any splashes immediately.
Women of childbearing potential and breast-feeding women should not handle the
veterinary medicinal product or should wear impervious gloves when administering
the veterinary medicinal product.
People with known hypersensitivity to cabergoline or any of the other ingredients in
the veterinary medicinal product should avoid contact with the veterinary medicinal
product.
Do not leave unattended filled syringes in the presence of children. In case of
accidental ingestion, particularly by a child, seek medical attention immediately and
show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine
receptors, the veterinary medicinal product should not be administered concurrently
with drugs which have dopamine antagonist activity (such as phenothiazines,
butyrophenones, metoclopramide), as these might reduce its prolactin inhibiting
effects. See also section 3.3.
Since cabergoline may induce transient hypotension, the veterinary medicinal
product should not be used in animals concurrently treated with hypotensive drugs.
See also section 3.3 and 3.6.

Do not store above 30 °C.
Keep the bottle in the outer carton in order to protect from light.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.